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Abstract The new protein carrier was developed on the basis of
recombinant RNA phage QL capsid. C-terminal UGA extension
of the short form of QL coat, so-called A1 extension, served as a
target for presentation of foreign peptides on the outer surface of
mosaic QL particles. In conditions of enhanced UGA suppres-
sion, the proportion of A1-extended to short coats in mosaic
particles dropped from 48% to 14%, with an increase of the
length of A1 extension. A model insertion, short preS1 epitope
31-DPAFR-35 of hepatitis B surface antigen, demonstrated
superficial location on the mosaic QL particles and ensured
specific antigenicity and immunogenicity.
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1. Introduction
Recombinant coats of icosahedral RNA bacteriophages of
the Leviviridae family are of obvious interest in protein engin-
eering as putative carriers of foreign peptides [1^4]. First of
all, owing to their highly-resolved X-ray structures (for review
see [5]). Leviviridae phages are subdivided into Levivirus (se-
rological groups I and II) and Allolevivirus (serological groups
III and IV), but virions of both genera are icosahedrons with
quasi T=3 symmetry, consisting of 180 copies of coat protein
enveloping a complex of single-stranded genomic RNA and
maturation protein. In contrast to Levivirus, Allolevivirus vi-
rions contain three to ¢ve molecules of the prolonged coat, so-
called A1 protein, with 196 aa residues of the A1 extension
added C-terminally to the short form of coat protein [6].
These extended molecules are formed as a result of natural
read-through of the opal (UGA) terminator of the coat pro-
tein [7]. Although the biological function of A1 protein is not
understood, it is believed to be involved in the Allolevivirus
infection process [8,9].
Recombinant coats of two representatives of Levivirus ge-
nus, MS2 and fr, were employed recently as peptide carriers.
MS2 capsids accepted 9 aa residues inserted into the external
N-terminal hairpin between L-sheets A and B [4], whereas fr
coats allowed insertions of a least (i) 19 aa at the N-terminus,
(ii) 5 aa at position 51, and (iii) 3 aa at the C-terminus of the
molecule [1,3]. However, the extremely rigid structure of ico-
sahedrons of these phages [5] complicated further develop-
ment of these models. Here, we propose recombinant coats
of QL phage, a typical representative of Allolevivirus genus, as
more attractive candidates for peptide presentation, with the
use of A1 extensions as targets for foreign insertions. Recent
X-ray structure of QL virions showed that the monomers of
coat protein assume three di¡erent conformations A, B and C,
forming two types of dimers [10], similar to Levivirus particles
[5]. Nevertheless, QL dimers, di¡ering from Levivirus dimers,
are linked in pentamers and hexamers by disul¢de bonds [10].
The minority and asymmetric location of A1 protein were
reasons why X-ray analysis failed to locate it. The structural
similarity of A1 extensions but not the short forms of their
coat proteins to super¢cially located proteins, such as hepati-
tis B surface antigen (HBsAg) preS1 region, especially in the
speci¢c stretch responsible for the attachment of HBV virions
to hepatocytes [2], suggested their exterior location on the
phage virions. We attempted to mark A1 extensions with a
short foreign epitope, the peptide 31-DPAFR-35 from the
preS1 region of HBsAg in order to evaluate presentation cap-
abilities of A1 protein. Moreover, we enhanced strongly the
number of A1 extensions within the mosaic QL particles in
conditions of strong UGA suppression.
2. Materials and methods
2.1. Antibodies
Polyclonal anti-QL antibodies were generated by immunization of
rabbits with puri¢ed QL capsids encoded by the UAA-terminated
short form of QL C gene [2].
2.2. Construction of plasmids
The plasmid pQLGGA was created by site-directed mutagenesis.
Upstream primers: 5P-CAGCTGAACCCAGCGTACGGAACACT-
G-3P, 5P-TAATACGACTCACTATAGGG-3P and downstream prim-
er: 5P-AACATCAAATTCGCGAGGCTGG-3P were used for the syn-
thesis of mutant PCR-fragment that was reintroduced into the pQL
expression vector at the unique restriction sites XbaI, and HindIII.
Two sets of plasmids pQLUGA and pQLGGA were created by two
steps of PCR. The upstream primer (5P-CAGACCGGAATTC-
GAGCTCGCC-3P) was the same in all of the PCR reactions. The
downstream primers of the ¢rst step of PCR were 5P-GGATCGCTC-
GAGCCTGAGCCTCAor(TCC)ATACGCTGGGTTCAGCT-3P for
QLUGA11 and QLGGA11; 5P-GCAGGATCGCTCGAGCCTGAG-
CCACCACCGGCAATG-3P for QLUGA18 and QLGGA18; 5P-TC-
GAAAAGCAGGATCCGGAATAACCGGATCGGG-3P for QLU-
GA24 and QLGGA24 construction. The products of the ¢rst PCR
were used as matrices for the second PCR reactions. The downstream
primer 5P-GCGCGAAGCTTATCGGAATGCAGGATCGCTCGA-
GCCTGAG-3P was used in the second PCR reactions for construc-
tions QLUGA11, QLGGA11, QLUGA18 and QLGGA18, and the
primer 5P-GCGAAGCTTAATTAATTATCGAAAAGCAGGATC-
CGG-3P for construction of QLUGA24 and QLGGA24. The products
of the second PCR were digested with XbaI and HindIII, and cloned
into the QL expression vector cleaved by XbaI and HindIII. Plasmids
pQLUGA203, pQLGGA203 were created by BglII digestion of pQL
and its GGA-containing form, with subsequent insertion of a syn-
thetic DNA copy of the preS1 sequence 31-DPAFRA-36 with sticky
BglII ends into the BglII restriction site.
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2.3. Expression and puri¢cation of mosaic QL particles
E. coli JM109 cells harboring the appropriate plasmids were grown
overnight in M9-medium supplemented with 10 g/l Casamino acids
(Difco). E. coli lysates were prepared by grinding with aluminium
oxide (Alcoa A-305, Serva) and sonication of cells incubated for
30 min on ice in lysis bu¡er (10 mM Tris-HCl, pH 8.0, 5 mM
EDTA, 150 mM NaCl, 0.02% Triton X-100, 2 mg/ml lysozyme). After
centrifugation, proteins were precipitated from the supernatant with
ammonium sulfate at 50% saturation over 0.5 h at 4‡C. Pellets were
resuspended in 4 ml of PBS. Chimeric QL particles were puri¢ed on
Sepharose CL-4B (Pharmacia Biotech) column (1.8U95 cm).
2.4. Electron microscopy
For direct electron microscopy, capsids were stained in 2% phos-
photungstic acid. For immunogold detection of epitopes, capsids were
incubated with a monoclonal anti-preS1 MA18/7 antibody, developed
with gold-labelled goat anti-mouse IgG and negatively stained in 2%
uranylacetate.
2.5. SDS-PAGE and Western blotting
Laemmli’s electrophoresis on 15% gel, Western blotting, and stain-
ing with Coomassie brilliant blue G-250, were performed according to
standard protocols.
2.6. Competitive ELISA
Microtiter 96-well plates were coated with synthetic HBV (subtype
ayw) preS1 peptide p21^47 (1 Wg/well) and blocked overnight with
0.5% BSA (Pharmacia) at 4‡C. Wells were washed with PBS bu¡er
containing 0.5% Tween-20. Aliquots of recombinant capsids and p21^
47 peptide as a positive control were added at varying dilutions to-
gether with MA18/7 antibody diluted 1:15 000. After 1 h incubation
at 37‡C, the wells were washed, and anti-mouse Ig horseradish per-
oxidase conjugate (Amersham) was added. Plates were incubated for
1 h at 37‡C, then washed, and 100 Wl/well of o-phenylenediamine
dihydrochloride (Sigma) was added. Inhibition of MA18/7 antibody
binding to p21^47 peptide by recombinant capsids or by control pep-
tide p21^47 was calculated according to the following equation: %
inhibition = 100U(13(OD492 with inhibition3bkgd)/(OD492 without
inhibition3bkgd)), where the bkgd was the absorbance from wells
coated with BSA only.
2.7. Immunization
Inbred Balb/C mice were immunized by i.p. injection of 20 Wg of
chimeric proteins in CFA and boosted with a half-dose of proteins in
IFA on days 10, 24. For detection of antibody titers, p21^47 peptide
was coated on microtiter plates. Pooled murine sera, collected on day
24 were titrated at di¡erent dilutions. The data were expressed as
antibody titer representing the highest dilution to yield three times
the OD reading of preimmunization sera.
2.8. Computer analysis
The matrix program (BioCan Scienti¢c) was employed for determi-
nation of the ratio of A1-extended to short forms of QL coat protein
on Western blots.
3. Results
3.1. Construction of QL display vectors
Fig. 1 shows the structure of two sets of vectors used for the
expression of extended coat proteins of di¡erent length. Vec-
tor pQL [11], with the cloned full-length QL gene C located
under the control of E. coli trp operon and T7 phage pro-
moters, was used as the initial plasmid for these constructions.
One set of vectors (QLUGA) was designed for the generation
of mosaic particles and consisted of modi¢ed A1 genes retain-
ing UGA terminator. The other set (QLGGA) was con-
structed for the expression of full-length and shortened A1
genes, without any translational read-through. In this case,
site-directed mutagenesis was used to change the stop UGA
codon of the short form of coat protein to the sense GGA
codon.
A synthetic DNA copy of HBV preS1 epitope 31-DPAFR-
35, corresponding to the minimal sequence that is necessary
and su⁄cient to be recognized by the monoclonal virus-neu-
tralizing anti-preS1 antibody MA18/7 [12], was introduced
into the unique restriction sites at various positions of A1
extension. Deletions of 177 aa (QLUGA24 and QLGGA24),
183 aa (QLUGA18 and QLGGA18) and 190 aa (QLUGA11
and QLGGA11) at the C-terminus of A1 were undertaken
with the aim to estimate the role of the size of A1 extensions
in capsid-forming ability of modi¢ed A1 proteins formed in
both sets of vectors.
3.2. Capsid-forming ability of modi¢ed A1 proteins
Products encoded by plasmids of the QLGGA series (Fig. 1)
SDS-PAGE, Western blotting and electron microscopy
showed that both initial A1 proteins and their full-length
form with the DPAFR insertion were unable to form capsids,
remained insoluble and formed inclusion bodies, whereas
shortened A1 variants with the 24, 18, 11 aa extensions
were soluble and appeared as asymmetric particles that dif-
fered strongly from icosahedral phage-like shells in size and
shape.
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Fig. 1. Two sets of QL display vectors constructed on the basis of
cloned full-length gene C. The structure of the initial pQL plasmid
is shown above. Designations for the appropriate vectors of the ¢rst
set of UGA-containing read-through genes and of the second set of
GGA-containing genes are shown above and under the line, respec-
tively. The numbers of aa residues (including UGA- or GGA-en-
coded residue from A1 extension) preceding the inserted preS1 epit-
ope 31-DPAFR-35 (shown as black bar) are given. Restriction sites
enclosing the preS1 epitope 31-DPAFR-35 are shown.
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3.3. Capsid-forming ability of modi¢ed A1 proteins in the
presence of short coats
To enhance the expression of A1-extended read-through
genes and, therefore, the content of the appropriate A1-ex-
tended proteins in mosaic particles, we used the plasmid
pISM3001 which harbors cloned opal tRNA gene under the
control of lac promoter and enables translation of UGA co-
don as a sense tryptophan codon [13]. Quantitative analysis of
products encoded by plasmids of the QLUGA series (Fig. 1)
in presence of pISM demonstrated that the UGA suppression
level was stable in all of the analyzed subclones, and the syn-
thesis of A1-extended read-through proteins increased up to
40% for QLUGA203, 48% for QLUGA24 and QLUGA18,
and 47% for QLUGA11 (Fig. 4).
The products of all mentioned particulation-competent QL
variants were puri¢ed by gel ¢ltration on a CL4B sepharose
column. Electron microscopy revealed their icosahedral na-
ture and phenotypic similarity to native QL virions and re-
combinant QL shells (Fig. 2). Quantitative Western blot anal-
ysis of the proportions of short and A1-extended forms of
coat proteins within the particles (Fig. 3) showed that these
particles were in fact mosaic, and the percentages of A1-ex-
tended coats reached 14% for a maximal 203 aa extension, but
the numbers of A1-extended coats increased to 47^48% for
the shorter 11, 18 and 24 aa extensions.
3.4. Antigenicity of mosaic particles
A competitive ELISA test of puri¢ed capsid-like particles
with monoclonal MA18/7 antibody (Fig. 4) was employed to
identify the localization of preS1 epitope on the capsids.
Quanti¢cation of competitive ELISA indicated that about
two third of inserted epitopes are accessible to antibody in
the case of 11, 18 and 24, and at least one third of them
are antibody-accessible in the case of 203 aa extension. Im-
munogold electron microscopy of mosaic particles with
MA18/7 antibody (Fig. 2) con¢rmed the super¢cial localiza-
tion of preS1 epitope attached to A1 extensions of di¡erent
length.
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Fig. 2. Negative staining (large photos, magni¢cation 200 000U)
and immunogold electron microscopy with monoclonal anti-preS1
MA18/7 antibodies (small photos, magni¢cation 300 000U) of mo-
saic particles puri¢ed from E. coli cells after expression of the ap-
propriate A1-extended genes under strong UGA suppression condi-
tions.
Fig. 3. Proportions of coat (CP) and extended coat (CP+exten-
sion[aa]) proteins in the crude E. coli cell SDS lysates (lines 1, 2, 4)
and pure capsids (lines 3, 5) expressed from plasmids of a QLUGA
series in the E. coli cells derived under e⁄cient UGA suppression
conditions: SDS-PAGE (line 1), Western blotting with polyclonal
QL antibodies (lines 2, 3) and with monoclonal anti-preS1 MA18/7
antibodies (lines 4, 5), and mathematical alignment (AP, BP, CP, DP).
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3.5. Immunogenicity of mosaic particles
The immunogenicity of mosaic particles was tested in Balb/
C mice, and their ability to induce anti-preS1 response was
detected by standard ELISA test (Fig. 4). Immunogenicity of
the preS1 insertion increased with the reduction of the length
of A1 extension. The highest immunogenicity was found for
mosaic particles harboring A1 proteins with only 11 aa exten-
sion (titer 1:3600 of speci¢c anti-preS1 antibodies). The im-
munogenicity of mosaic particles harboring A1 proteins with
18 and 24 aa extensions was a little bit lower (1:2000), and the
product with the longest 203 aa A1 extension showed remark-
able level (1:700) of anti-preS1 response.
4. Discussion
Normally the proportion of A1 read-through molecules
within QL virions was not strictly ¢xed and allowed an in-
crease from 1.6% to 15%, when an UGA suppressor strain
was used as a host [6]. Although the low number and irregu-
larity of A1 extensions made them invisible to X-ray analysis,
the crystal structure of the QL particle indicated that the C-
termini of the short form of the coat protein, where the read-
through A1 extension would be expected, are located on the
surface of the capsid. However, the C-termini of QL CP were
shielded from the exterior to some extent by the N-termini of
the co-operating monomer within the dimeric unit [10]. There-
fore, spatial limitations may explain why we found that not
only full-length A1 proteins are insoluble in the absence of
short CP, but also short 11 aa extensions are su⁄cient to
block self-assembly. In the case of QLUGA series vectors, at
enhanced UGA read-through, heterologous dimers may be
formed from helper and extended CP. The number of ac-
cepted A1-extended proteins depended, however, on the
length of extension, and increased from 14% to 48%, with a
decrease of its length from 203 to 24 aa residues (Fig. 3). The
percentages of A1-extended proteins in the cells and in the
puri¢ed particles ¢t well in the case of short extensions (Fig.
3, parts BP, CP, DP), indicating the absence of any particula-
tion advantage for short CP in these cases. In contrast, long
A1-extended protein (Fig. 3, part AP) was disadvantageous for
self-assembly to short CP by a factor of about 3. The exterior
location of A1 extensions was proved experimentally by im-
munogold decoration of particles (Fig. 2) and by competitive
ELISA within speci¢c anti-preS1 monoclonal antibody (Fig.
4, parts A, B). Calculations given in Figs. 3 and 4 showed that
most, if not all A1-extended molecules are accessible to anti-
body within mosaic particles. The inserted model epitope also
showed remarkable immunogenicity in mice, in spite of its
minimal length (Fig. 4, part C). Historically, ¢lamentous coats
of DNA bacteriophages from the Inoviridae family and icosa-
hedral coats of cowpea mosaic virus from RNA plant viruses
were the ¢rst sources for construction of mosaic particles
[14,15]. Usage of mosaic technology allowed to enhance ca-
pacities of the gene VIII-encoded major protein of ¢lamentous
phage fd from 12 to 36 aa residues [16]. Introduction of a
modi¢ed gene III-encoded minor protein of ¢lamentous
phages having a capacity of approximately 57 aa residues
may be recognized as a special case of generation of mosaic
particles [14]. The number of gene III products within the
¢lamentous phage is constant and does not exceed ¢ve copies
[17], whereas mosaic QL particles can include about 25 to 86
copies of A1-extended proteins per shell. The capsid of the
popular cowpea mosaic virus can include 50% percent of the
small proteins with 27 aa insertion [15]. Another advantage of
the proposed model is its non-infectious character. QL coats
are able to self-assemble in the absence of genomic RNA,
unlike the ¢lamentous phages and cowpea mosaic virus, where
assembly is concomitant with encapsidation of a speci¢c ge-
nome [14^17]. Of the existing non-infectious mosaic models,
Jonsongrass mosaic virus [18], hepatitis B surface [19] and
core [20] antigens are worthy of notice, especially the latter
which exploits the same idea of C-terminal UGA extension.
Mosaic QL particles harboring epitope-marked A1 exten-
sions will open fresh opportunities for detailed structural
and functional study of protruding parts of viral coats.
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